Cambridge Epigenetix has now raised $56.5m from investors including the university and Alphabet’s GV for its epigenetics-powered diagnostic platform.
Cambridge Epigenetix, a UK-based epigenetic technology spinout of University of Cambridge, received $30m today in a series C round led by investment firm Ahren Innovation Capital and backed by unspecified existing investors.
Founded in 2012, Cambridge Epigenetix is developing an epigenetics-powered diagnostic screening platform that combines several tests for indications including cancer into a single blood-draw exam.
The test works by identifying instances of a DNA strand called 5-hydroxymethycytosine that can be linked to specific diseases.
Epigenetics…